DOYLESTOWN, Pa., Jan. 22, 2018 /PRNewswire/ — OrthogenRx, Inc., a medical device company focused on the development and commercialization of treatments for musculoskeletal conditions including osteoarthritis (OA) has announced the launch of TriVisc® (sodium hyaluronate) for the treatment of patients with osteoarthritic (OA) knee pain who have failed to get adequate relief from simple painkillers or from exercise …

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone